The Future of Sublingual Immunotherapy in the United States
- 560 Downloads
Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC). The Food and Drug Administration (FDA) in the USA has approved three SLIT tablets for the treatment of AR and ARC in relation to pollen. Specifically, Grastek® and Oralair® are two formulations approved to treat patients suffering with AR/ARC to grass pollen, and Ragwitek™ is a formulation approved to treat patients suffering with AR/ARC to ragweed pollen. Although these approvals provide support for physicians to prescribe SLIT, barriers to prescribing SLIT still remain such as FDA approval for additional formulations, a standard dose and dosing schedule, and cost/insurance coverage. In order to further support the use of SLIT, research is currently being conducted to expand the indication for SLIT to other common comorbidities to AR/ARC. For example, allergic asthma, food allergies, and atopic dermatitis are other diseases which are being explored. The future of SLIT in the USA is unknown; however, education will be necessary for both providers and patients.
KeywordsSublingual immunotherapy Allergic rhinitis Allergic rhinoconjunctivitis Allergen immunotherapy
Compliance with Ethics Guidelines
Conflict of Interest
Nicole Pleskovic and Ashton Bartholow declare that they have no competing interests. Deborah A. Gentile reports that she was a speaker for Merck & Co. and Greer. David P. Skoner reports grants from Greer Laboratories, Novartis, Merck & Co., Genentech, GlaxoSmithKline, Sunovion, and Teva, and was a speaker or consultant for Merck & Co., Sunovion, Mylan, Teva, GlaxoSmithKline, Genentech, Novartis, and Sunovion.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy world allergy organization position paper. WAO J. 2009;2:233–81.Google Scholar
- 7.•Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155–67. The authors performed a meta-analysis to study SLIT and the therapy’s effectiveness and safety in asthmatics, rhinitis, conjunctivitis, and children.PubMedCentralPubMedCrossRefGoogle Scholar
- 9.•Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014;10:1309–24. This article summarizes all key parts of grass pollen SLIT including the formulations Oralair® and Grazax™/Grastek® from their efficacy, safety, research trials, and cost-effectiveness.PubMedCrossRefGoogle Scholar
- 10.••Creticos PS, Corren J, Feldweg AM. Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. UpToDate. 2014. This article evaluates SLIT completely—from the background to different formulations. It is an all-encompassing article highlighting delivery formulations, doses, and concomitant diseases. The article also goes into detail regarding the FDA-approved SLIT formulations.Google Scholar
- 14.••Leatherman B, Skoner DP, Hadley JA, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. Int Forum Allergy Rhinol. 2014;4:779–88. The AIRS surveys collected important knowledge of both providers and patients about AR/ARC and immunotherapy. The article highlights the view of providers on allergen immunotherapy.PubMedCrossRefGoogle Scholar
- 22.Bousquet J, Khaltaev N, Cruz AA, Denburg J, et al. Allergic rhinitis and its impact on Asthma (ARIA) 2008 update. Eur J Allergy Clin Immunol. 2008;63:Supplement 86, 8–160.Google Scholar
- 26.Corp MS& D. Biologic License Application (BLA) for Timothy grass pollen allergen extract tablet for sublingual use. FDA Brief Doc. 2013.Google Scholar
- 31.•Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety, and cost. J Eval Clin Pract. 2014;20:225–38. This is a valuable meta-analysis performed on Oralair®, Grazax™, and SCIT. It examines and compares the efficacy, safety, and cost of the three medications.PubMedCrossRefGoogle Scholar
- 45.Narisety SD, Frischmeyer-guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135:1275–82.Google Scholar
- 46.Burks AW, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;1–12.Google Scholar
- 50.•Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol. 2007;156:674–81. This study showed the effects or house dust mite SLIT in adults with allergic rhinitis. The 300IR and 500IR levels show a significant improvement in symptoms after 1 year of treatment, and this effectiveness was maintained in the second year without the therapy.PubMedCrossRefGoogle Scholar
- 51.Bergmann K-C, Demoly P, Worm M, Fokkens W, Carrillo T. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Am Acad Allergy Asthma Immunol. 2013;133:1608–14.Google Scholar
- 52.Cingi C, Bayar Muluk N, Ulusoy S, et al. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. Eur Arch Oto-Rhino-Laryngology. 2014.Google Scholar
- 57.Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Am Acad Allergy Asthma Immunol. 2013;132:1322–36.Google Scholar